Skip to main content
. 2004 Dec;63(12):1564–1570. doi: 10.1136/ard.2003.017269

Figure 4.

Figure 4

 Chronic inflammation—therapeutic administration: (A) knee joint swelling; (B) urinary NOx; and (C) PGE2, expressed as a percentage change compared with pre-injection values in response to intra-articular injection of FCA. There was significant joint swelling and increased NOx and PGE2 production in vehicle, L-NIL (43 mg/kg), and SC-236 (5.6 mg/kg) therapeutically treated groups. A non-inflamed, untreated group is included for comparison. Values represent means (SEM).

HHS Vulnerability Disclosure